Image 5_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Image 3_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Image 4_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

The Vancouver Scar Scale. by Na Wang (193263)

Subjects:

S1 Dataset - by Na Wang (193263)

Subjects:

Numerical Rating Scale (NRS). by Na Wang (193263)

Subjects:

Mammary fistula (n(%)). by Na Wang (193263)

Subjects:

Forest maps affecting lactation outcomes. by Na Wang (193263)

Subjects:

Postoperative drainage(ml) (M(IQR)). by Na Wang (193263)

Subjects:

Effect of Oxamate, LBP, or their combination on partial glycolysis metabolites in A549 and NCL-H1975 cells after 24 hours of treatment. by Siyu Yuan (7425719)

Subjects:

Changes in the growth of two oat varieties under drought stress and normal water supply treatments. by Caijin Chen (3107787)

Subjects:

Line graph illustrating mean body weight (in grams) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean food intake (g) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

EF-24 treatment disrupts key molecular pathways associated with cell survival, proliferation, and viability. by Ajeet P. Singh (22298432)

Subjects:

Fig 10 - by Farshid Maleki (20521649)

Subjects:

Fig 4 - by Farshid Maleki (20521649)

Subjects:

Fig 9 - by Farshid Maleki (20521649)

Subjects:

Fig 6 - by Farshid Maleki (20521649)

Subjects:

Demographic characteristics of the participants. by Ji Woong Chang (1829314)

Subjects: